Consilium Wealth Advisory LLC Sells 782 Shares of Eli Lilly and Company (NYSE:LLY)

Consilium Wealth Advisory LLC lessened its holdings in Eli Lilly and Company (NYSE:LLY) by 19.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,200 shares of the company’s stock after selling 782 shares during the quarter. Eli Lilly and Company makes up approximately 1.2% of Consilium Wealth Advisory LLC’s holdings, making the stock its 23rd biggest holding. Consilium Wealth Advisory LLC’s holdings in Eli Lilly and Company were worth $2,470,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. AMF Tjanstepension AB grew its holdings in Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock valued at $293,964,000 after purchasing an additional 176,552 shares during the period. Values Added Financial LLC grew its holdings in Eli Lilly and Company by 4.9% during the third quarter. Values Added Financial LLC now owns 366 shares of the company’s stock valued at $324,000 after purchasing an additional 17 shares during the period. Pallas Capital Advisors LLC grew its holdings in Eli Lilly and Company by 8.6% during the third quarter. Pallas Capital Advisors LLC now owns 16,686 shares of the company’s stock valued at $14,873,000 after purchasing an additional 1,319 shares during the period. Worth Financial Advisory Group LLC acquired a new position in Eli Lilly and Company during the third quarter valued at approximately $629,000. Finally, Smith Group Asset Management LLC grew its holdings in Eli Lilly and Company by 46.6% during the third quarter. Smith Group Asset Management LLC now owns 2,189 shares of the company’s stock valued at $1,939,000 after purchasing an additional 696 shares during the period. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LLY. Berenberg Bank set a $970.00 price target on shares of Eli Lilly and Company in a report on Thursday, January 16th. Redburn Atlantic upgraded shares of Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Wolfe Research began coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Finally, Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a report on Monday, February 3rd. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average price target of $1,000.28.

Eli Lilly and Company Stock Up 1.5 %

LLY stock opened at $915.47 on Thursday. The stock has a market capitalization of $868.02 billion, a P/E ratio of 78.18, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The firm has a 50-day moving average price of $808.88 and a 200-day moving average price of $848.46.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.66%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s dividend payout ratio is 51.24%.

Eli Lilly and Company declared that its board has approved a share repurchase program on Monday, December 9th that authorizes the company to repurchase $15.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 2% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s management believes its shares are undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.